NR 565 ADVANCED PHARMACOLOGY
FUNDAMENTALS – CHAMBERLAIN
COLLEGE OF NURSING: FINAL
COMPREHENSIVE EXAMINATION – 100
VERIFIED QUESTIONS WITH CORRECT
ANSWER RATIONALES (2026/2027)
QUESTION 1
A 55-year-old patient with newly diagnosed type 2 diabetes has an A1C of 7.4%
and no significant comorbidities. Which initial pharmacologic approach is most
appropriate in addition to lifestyle changes?
A. Begin insulin therapy immediately
B. Begin metformin monotherapy
C. Begin sulfonylurea therapy
D. Begin GLP-1 receptor agonist therapy
Answer: B. Begin metformin monotherapy
Rationale: Metformin is recommended as first-line pharmacologic therapy for most
patients with type 2 diabetes who have mild to moderate hyperglycemia (A1C
<7.5%) and no contraindications. It is effective, safe, inexpensive, and does not cause
weight gain or hypoglycemia. Insulin is not first-line for newly diagnosed type 2
diabetes. Sulfonylureas and GLP-1 agonists are appropriate as add-on therapy or
alternatives, but metformin remains the preferred initial agent.
QUESTION 2
,A 62-year-old patient with type 2 diabetes and obesity is already on metformin.
You want to add a medication that promotes weight loss and improves
glycemic control without significant hypoglycemia risk. Which class best fits
this goal?
A. Sulfonylureas
B. Thiazolidinediones
C. GLP-1 receptor agonists
D. Meglitinides
Answer: C. GLP-1 receptor agonists
Rationale: GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve glycemic
control, slow gastric emptying, decrease appetite, and are associated with weight loss
rather than weight gain. They have a low risk of hypoglycemia when used alone or
with metformin. Sulfonylureas and meglitinides can cause weight gain and
hypoglycemia. Thiazolidinediones cause fluid retention and weight gain.
QUESTION 3
A 76-year-old patient with long-standing diabetes, CKD, and coronary artery
disease has a history of multiple severe hypoglycemic episodes. Which A1C
target is most reasonable?
A. <6.5%
B. <7.0%
C. <7.5%
D. <8.0%
Answer: D. <8.0%
Rationale: In older adults with extensive comorbidities (CKD, CAD) and high risk of
hypoglycemia, a less stringent A1C goal such as <8% is often safer and more
appropriate. Tight glycemic control (e.g., <6.5%) increases hypoglycemia risk without
,meaningful benefit in this population. Individualization of glycemic targets based on
patient factors is essential.
QUESTION 4
Why are sulfonylureas ineffective in patients with type 1 diabetes?
A. They require functioning pancreatic beta cells
B. They are destroyed by gastric acid in type 1 patients
C. They have no effect on insulin receptors
D. They are metabolized too quickly in type 1 patients
Answer: A. They require functioning pancreatic beta cells
Rationale: Sulfonylureas stimulate insulin release from pancreatic beta cells by
closing ATP-sensitive potassium channels. In type 1 diabetes mellitus, autoimmune
destruction of beta cells results in absent or nonfunctional beta cells, making these
medications ineffective. They do not work through insulin receptors or have issues
with metabolism specific to type 1 diabetes.
QUESTION 5
What is the primary difference between meglitinides and sulfonylureas in terms
of pharmacokinetics?
A. Route of administration
B. Duration of action
C. Mechanism of action
D. Site of metabolism
Answer: B. Duration of action
, Rationale: Meglitinides (e.g., repaglinide) are short-acting insulin secretagogues with
a rapid onset and short duration (2-4 hours), aimed at controlling postprandial
glucose. Sulfonylureas generally have a longer duration of action (up to 24 hours for
some agents). Both are oral medications that work by stimulating insulin secretion,
but their pharmacokinetic profiles differ significantly.
QUESTION 6
A patient with diabetes and hypertension is started on a nonselective beta
blocker. What is the primary concern related to glycemic management?
A. Increased risk of hyperglycemia
B. Masking of adrenergic symptoms of hypoglycemia
C. Increased insulin resistance
D. Decreased effectiveness of metformin
Answer: B. Masking of adrenergic symptoms of hypoglycemia
Rationale: Nonselective beta blockers (e.g., propranolol) blunt tachycardia, tremor,
and other adrenergic symptoms that serve as early warnings of low blood glucose.
They can also impair hepatic glucose release during hypoglycemia, prolonging
recovery. This masking effect is the primary concern, as patients may not recognize
hypoglycemia until neuroglycopenic symptoms (confusion, seizure) develop.
QUESTION 7
A pregnant patient in the first trimester presents with hyperthyroidism
symptoms. What treatment option should the nurse practitioner consider?
A. Radioactive iodine ablation
B. Propylthiouracil (PTU)
C. Methimazole
D. Thyroidectomy
FUNDAMENTALS – CHAMBERLAIN
COLLEGE OF NURSING: FINAL
COMPREHENSIVE EXAMINATION – 100
VERIFIED QUESTIONS WITH CORRECT
ANSWER RATIONALES (2026/2027)
QUESTION 1
A 55-year-old patient with newly diagnosed type 2 diabetes has an A1C of 7.4%
and no significant comorbidities. Which initial pharmacologic approach is most
appropriate in addition to lifestyle changes?
A. Begin insulin therapy immediately
B. Begin metformin monotherapy
C. Begin sulfonylurea therapy
D. Begin GLP-1 receptor agonist therapy
Answer: B. Begin metformin monotherapy
Rationale: Metformin is recommended as first-line pharmacologic therapy for most
patients with type 2 diabetes who have mild to moderate hyperglycemia (A1C
<7.5%) and no contraindications. It is effective, safe, inexpensive, and does not cause
weight gain or hypoglycemia. Insulin is not first-line for newly diagnosed type 2
diabetes. Sulfonylureas and GLP-1 agonists are appropriate as add-on therapy or
alternatives, but metformin remains the preferred initial agent.
QUESTION 2
,A 62-year-old patient with type 2 diabetes and obesity is already on metformin.
You want to add a medication that promotes weight loss and improves
glycemic control without significant hypoglycemia risk. Which class best fits
this goal?
A. Sulfonylureas
B. Thiazolidinediones
C. GLP-1 receptor agonists
D. Meglitinides
Answer: C. GLP-1 receptor agonists
Rationale: GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve glycemic
control, slow gastric emptying, decrease appetite, and are associated with weight loss
rather than weight gain. They have a low risk of hypoglycemia when used alone or
with metformin. Sulfonylureas and meglitinides can cause weight gain and
hypoglycemia. Thiazolidinediones cause fluid retention and weight gain.
QUESTION 3
A 76-year-old patient with long-standing diabetes, CKD, and coronary artery
disease has a history of multiple severe hypoglycemic episodes. Which A1C
target is most reasonable?
A. <6.5%
B. <7.0%
C. <7.5%
D. <8.0%
Answer: D. <8.0%
Rationale: In older adults with extensive comorbidities (CKD, CAD) and high risk of
hypoglycemia, a less stringent A1C goal such as <8% is often safer and more
appropriate. Tight glycemic control (e.g., <6.5%) increases hypoglycemia risk without
,meaningful benefit in this population. Individualization of glycemic targets based on
patient factors is essential.
QUESTION 4
Why are sulfonylureas ineffective in patients with type 1 diabetes?
A. They require functioning pancreatic beta cells
B. They are destroyed by gastric acid in type 1 patients
C. They have no effect on insulin receptors
D. They are metabolized too quickly in type 1 patients
Answer: A. They require functioning pancreatic beta cells
Rationale: Sulfonylureas stimulate insulin release from pancreatic beta cells by
closing ATP-sensitive potassium channels. In type 1 diabetes mellitus, autoimmune
destruction of beta cells results in absent or nonfunctional beta cells, making these
medications ineffective. They do not work through insulin receptors or have issues
with metabolism specific to type 1 diabetes.
QUESTION 5
What is the primary difference between meglitinides and sulfonylureas in terms
of pharmacokinetics?
A. Route of administration
B. Duration of action
C. Mechanism of action
D. Site of metabolism
Answer: B. Duration of action
, Rationale: Meglitinides (e.g., repaglinide) are short-acting insulin secretagogues with
a rapid onset and short duration (2-4 hours), aimed at controlling postprandial
glucose. Sulfonylureas generally have a longer duration of action (up to 24 hours for
some agents). Both are oral medications that work by stimulating insulin secretion,
but their pharmacokinetic profiles differ significantly.
QUESTION 6
A patient with diabetes and hypertension is started on a nonselective beta
blocker. What is the primary concern related to glycemic management?
A. Increased risk of hyperglycemia
B. Masking of adrenergic symptoms of hypoglycemia
C. Increased insulin resistance
D. Decreased effectiveness of metformin
Answer: B. Masking of adrenergic symptoms of hypoglycemia
Rationale: Nonselective beta blockers (e.g., propranolol) blunt tachycardia, tremor,
and other adrenergic symptoms that serve as early warnings of low blood glucose.
They can also impair hepatic glucose release during hypoglycemia, prolonging
recovery. This masking effect is the primary concern, as patients may not recognize
hypoglycemia until neuroglycopenic symptoms (confusion, seizure) develop.
QUESTION 7
A pregnant patient in the first trimester presents with hyperthyroidism
symptoms. What treatment option should the nurse practitioner consider?
A. Radioactive iodine ablation
B. Propylthiouracil (PTU)
C. Methimazole
D. Thyroidectomy
